Table 3.
Clinical characteristics between BG and placebo groups.
| Parameters | BG | Placebo | χ2-and t-value | P-value |
|---|---|---|---|---|
| Gender (male/female) | 32/28 | 34/26 | 0.135 | 0.714 |
| Age (year) | 39.89 ± 13.26 | 40.23 ± 12.78 | -1.303 | 0.179 |
| SBP (mm Hg) | 126.21 ± 11.52 | 130.54 ± 12.76 | -1.684 | 0.086 |
| DBP (mm Hg) | 87.23 ± 7.16 | 86.53 ± 7.48 | -1.296 | 0.158 |
| BMI | 24.91 ± 1.74 | 24.52 ± 1.48 | -1.563 | 0.098 |
| TC (mmol/L) | 5.52 ± 0.64 | 5.72 ± 0.87 | -0.618 | 0.274 |
| TG (mmol/L) | 2.24 ± 0.81 | 2.32 ± 0.94 | -2.158 | 0.109 |
| LDL-C (mmol/L) | 2.01 ± 0.64 | 2.35 ± 0.83 | -1.864 | 0.187 |
| HDL-C (mmol/L) | 1.84 ± 0.46 | 1.65 ± 0.32 | -2.619 | 0.074 |
| Cr (μmol/L) | 85.24 ± 13.58 | 87.04 ± 14.51 | -1.244 | 0.136 |
| HbA1C (%) | 8.42 ± 0.73 | 8.72 ± 0.86 | -0.654 | 0.246 |
| ACE-In | 6 | 5 | 3.07 | 0.38 |
| ARBS | 3 | 7 | ||
| Beta-blockers | 4 | 3 | ||
| Diuretics | 8 | 4 | ||
| CRT | 6 | 9 | 0.68 | 0.41 |
| ICD | 2 | 4 | 0.18 | 0.68 |
Chi-square test and t-test were used to compare the significant difference between COG and CG groups. BMI, body mass index; ACE-In, angiotensin-converting enzyme; ARBS, angiotensin receptor blockers; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator. All data were presented as mean value ± SD. There were significantly statistical differences between two groups if P < 0.05.